Cabaletta Bio (CABA) Liabilities and Shareholders Equity (2018 - 2026)

Cabaletta Bio's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $165.1 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 10.79% year-over-year to $165.1 million; the TTM figure through Dec 2025 stood at $744.5 million (down 12.14% YoY), while the FY2025 annual figure was $165.1 million, down 10.79% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $165.1 million, down from $189.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $253.6 million in Q4 2023, with the low at $91.7 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $165.1 million (2025), against an average of $159.7 million.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 132.44% in 2024, then tumbled 31.32% in 2025.
• Cabaletta Bio's Liabilities and Shareholders Equity stood at $126.3 million in 2021, then dropped by 7.42% to $117.0 million in 2022, then soared by 116.85% to $253.6 million in 2023, then dropped by 27.05% to $185.0 million in 2024, then decreased by 10.79% to $165.1 million in 2025.
• Business Quant data shows CABA's Liabilities and Shareholders Equity at $165.1 million in Q4 2025, $189.8 million in Q3 2025, and $224.5 million in Q2 2025.